戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 se 14 sessions (5 mg/kg/day via s.c. osmotic minipump).
2 icotine free base, 15 to 22 days via osmotic minipump).
3  delivered subcutaneously through an osmotic minipump.
4       h-1) or vehicle for 3 weeks by osmotic minipump.
5 almefene or vehicle for 7 days by an osmotic minipump.
6 mice 125 mg/kg of bleomycin via s.c. osmotic minipump.
7 dministered the drug for 3 weeks via osmotic minipump.
8  lateral ventricle via the implanted osmotic minipump.
9 lly relevant doses, administered via osmotic minipump.
10 ously by remote activation of an implantable minipump.
11 ation via a subcutaneously implanted osmotic minipump.
12 elivered from a surgically implanted osmotic minipump.
13 re administered exogenously via an implanted minipump.
14 red saline (control) was started using Alzet minipumps.
15  (100 microg x kg(-1) x day(-1)) via osmotic minipumps.
16  or by continuous s.c. infusion from osmotic minipumps.
17 g recombinant IGF-I administered via osmotic minipumps.
18 anterior optic nerve with osmotically driven minipumps.
19 f either saline or Angiotensin II by osmotic minipumps.
20 with NOD or vehicle administered via osmotic minipumps.
21 tensinII for 42 days using implanted osmotic minipumps.
22 lied by subcutaneous implantation of osmotic minipumps.
23 to adult male rats for two weeks via osmotic minipumps.
24 trol TAT peptide, or deltaV1-1 using osmotic minipumps.
25 infused with morphine from implanted osmotic minipumps.
26 nfusion from implanted saline-filled osmotic minipumps.
27 ly to male Lewis rats for 6 days using Alzet minipumps.
28 hicle delivered intra-arterially via osmotic minipumps.
29 ii for 4 weeks using implanted catheters and minipumps.
30 inistered to apoE-deficient mice via osmotic minipumps.
31 13 d into Sprague-Dawley rats, using osmotic minipumps.
32  area over 2 weeks via chronically implanted minipumps (1-2.5 microgram/d), and the psychomotor stimu
33    In animals exposed to AngII using osmotic minipumps (2.0 mug/kg per min), myocardial CTGF mRNA pea
34 ng II was infused subcutaneously via osmotic minipumps (40 ng/min) for 13 days in two groups (N = 10
35                     We modeled 5-HTP SR with minipumps, 5-HTP IR with injections, and chronic SSRI wi
36 ere administered for 2 weeks with an osmotic minipump 72 h after streptozotocin treatment.
37 al of recombinant Emc10 delivered by osmotic minipumps after MI in heart failure-prone FVB/N mice.
38 lution or to the decrease in rabbits without minipumps (analysis of covariance, P = 0.0092).
39 roups received Ang II infusions via a second minipump and drinking water+/-losartan.
40 de (25 mg/kg/day) subcutaneously via osmotic minipump and studied 20-22 h later for rotational behavi
41 ered intracerebroventricularly using osmotic minipumps and then tested the rats during week 2 of ster
42 erm isoprenaline stimulation through osmotic minipumps, and after incubation of rat neonatal cardiomy
43 or vehicle (VEH) was administered by osmotic minipumps, and CNV formation was measured 11 days after
44 fused by intraperitoneally implanted osmotic minipumps, and the resulting circulating concentrations
45 infusing isoproterenol (ISO) for 10 days via minipumps, and then animals were allowed to recover for
46 ith NT-3 or NT-4/5 for 8-35 d via an osmotic minipump attached to its central end at the time of axot
47 mbled peptide, were administered via osmotic minipumps (AV-Shunt(Gap27) or AV-Shunt(Scr)) for 4 weeks
48  subcutaneously to Galpha(q) mice by osmotic minipump beginning on day 12 of pregnancy and continuing
49                                   An osmotic minipump containing Ang II (1.44 mg/kg per day) was impl
50 went subcutaneous implantation of an osmotic minipump containing either vehicle or leptin at a dose (
51 /HeN mice were implanted subcutaneously with minipumps containing an inhibitor of nitric oxide, NG-ni
52 ague-Dawley rats were implanted with osmotic minipumps containing either vehicle, a cell-permeant pep
53 al rabbits implanted with osmotically driven minipumps containing endothelin-1 (0.1 microgram/day).
54                      In the first set, Alzet minipumps containing no PRL, wild-type (WT) PRL, or the
55                             On day 18, Alzet minipumps containing no PRL, WT PRL, or S179D PRL were i
56            C57BL/6J mice were implanted with minipumps containing saline or a slow-pressor dose of an
57 ing testosterone (T) or nothing, and osmotic minipumps continuously infusing MK-801, a noncompetitive
58  KOR agonist, over 5 days through an osmotic minipump decreased the amount of NREM and REM sleep and
59 ing, we surgically implanted rats with Alzet minipumps delivering (+)-naltrexone (0, 7.5, 15, 30 mg/k
60 eceptor subunits were implanted with osmotic minipumps delivering 24 mg x kg(-1) x d(-1) nicotine for
61 genous IGF-I concentrations or by implanting minipumps delivering an IGF-1 analogue, R(3)-IGF-1, whic
62 containing cells were implanted with osmotic minipumps delivering AngII (600 ng/kg/min) or saline for
63 anted subcutaneously with pellets or osmotic minipumps delivering morphine displayed time-related tac
64 id adventitia, and 2 days later we implanted minipumps delivering vehicle or Ang II (750 microg/kg pe
65 randomly selected and implanted with osmotic minipumps delivering vehicle or serelaxin for another 4
66 d-induced "pain"); placebo pellets or saline minipumps did not change thresholds.
67  that chronic delivery of (+)-naltrexone via minipumps during the withdrawal phase decreased incubate
68 micromol x kg(-1) x d(-1)) by use of osmotic minipumps (each n=7).
69 on induced by Ang II delivered by an osmotic minipump for 10 days (139 +/- 3 versus 153 +/-2 mmHg in
70 nfusion of anti-NPCT (16 mug per hour) via a minipump for 18 hours.
71                 Rats were treated by osmotic minipump for 21 d with the selective serotonin reuptake
72 ght external carotid artery using an osmotic minipump for 24 h.
73 re infused with Ang II or saline via osmotic minipump for 28 days, then functional and molecular chan
74  via intrathecal lumbar catheter and osmotic minipump for 4 months.
75 y protein transfer into peritoneal cavity by minipump for 4 weeks.
76 ecretin (2.5 nmoles/kg/day by way of osmotic minipumps for 1 week), and biliary mass was evaluated.
77 (1) antagonist Candesartan, s.c. via osmotic minipumps for 14 days, to determine whether peripheral c
78 7beta-estradiol (E2), or vehicle using Alzet minipumps for 2 weeks.
79 he mice via subcutaneously implanted osmotic minipumps for 28 days.
80 hanol (26 nmol microliter-1 h-1) via osmotic minipumps for 3 days.
81 tracerebroventricularly (i.c.v.) via osmotic minipumps for 3 days.
82 6 mg kg(-1) day(-1) ) or vehicle via osmotic minipumps for 3 weeks.
83 or bovine serum albumin (BSA) was infused by minipumps for 7 days to rats and we measured cholangiocy
84 or vehicle (CON) was administered by osmotic minipumps for 8 d to pair-fed adult rats.
85 re administered 25mug/kg/day BPA via osmotic minipumps from gestational day 8 through postnatal day (
86 ed by subcutaneous infusion using an osmotic minipump implanted 3 d before the induction of diabetes
87 odeoxyuridine (BrdU) delivered by an osmotic minipump implanted in the mother; cell birth dates were
88  AngII (60 ng/min) or vehicle via an osmotic minipump implanted subcutaneously in the dorsum of the n
89 ow was determined in two rabbits that had no minipump implants.
90 s after chronic nicotine exposure by osmotic minipump in adult and periadolescent rats.
91 were included to monitor the efficacy of the minipumps in raising plasma leptin in B6 mice.
92 ensitization) or continuously via an osmotic minipump (induces tolerance).
93            Methods: Mice were implanted with minipumps, infused with angiotensin-II/phenylephrine (An
94 s post-lactation were implanted with osmotic minipumps infusing either naltrexone (NTX) (70 microg/h)
95 egnant rats were given nicotine by implanted minipump infusion either from gestational days 4-12 or 4
96                                              Minipump infusion of angiotensin II to Ren1c-/- mice res
97 ntrols (vehicle, single bolus, or continuous minipump infusion of trophic factor, or killed cell graf
98 nt (daily injections) or continuous (osmotic minipump infusion).
99 poration of 5-bromodeoxyuridine (BrdU; 7-day minipump infusion).
100 d nicotine to adolescent rats via continuous minipump infusions from PN30 to PN47.5, using 6 mg/kg/da
101 o pregnant or adolescent rats via continuous minipump infusions, using dose rates that replicate the
102             In addition, we infused VEGF via minipump into the adult cortex.
103 by implantation of a bacteria-filled osmotic minipump into the peritoneal cavity.
104 nfusion of angiotensin II (AngII) by osmotic minipump into the subcutaneous space of mice at doses ra
105               We infused oxytocin by osmotic minipump into vasopressin-deficient Brattleboro rats for
106 ed Ang II or vehicle for 1 month via osmotic minipumps into mature apoE(-/-) mice.
107 , 7.13, 20.41 and 43.1 mg/kg/day via osmotic minipump or intermittently at 11.32 mg/kg/day via one da
108 er day) by means of an Alzet (Palo Alto, CA) minipump or vehicle [polyethylene glycol (PEG 300)] for
109  when c407 was administered both via osmotic minipumps or delivered orally prior to induction of dise
110 y of IL-2 into the mouse brain using osmotic minipumps or injection of mice with recombinant IL-2 pro
111 e, phencyclidine (PCP, 15 mg/kg/d by osmotic minipump), or PCP+glycine (16% by weight diet) intervent
112 as studied by infusing D-AP5 with an osmotic minipump over barrel cortex for 5 d of novel sensory exp
113 ived the vasopressin analog dDAVP by osmotic minipump plus either a daily water load (vasopressin esc
114  angiotensin II and isoproterenol by osmotic minipump produced increases in heart weight (15 and 45%,
115 ed subcutaneously over 22.75 h using osmotic minipumps producing steady state plasma concentrations o
116 infusion of insulin into the CNS via osmotic minipumps reduced the hepatic lipid content as assessed
117  were treated with relaxin (4 mug/h, osmotic minipump), relaxin plus PPARgamma inhibitor GW9662 (10 m
118 d as (1 mg/kg/day for 6 days) via an osmotic minipump starting at 0, 14 or 28 days of abstinence abst
119 aline was infused in TGA-PE rats via osmotic minipumps starting at day 13 of gestation (GD).
120 o address these issues, we implanted osmotic minipumps subcutaneously to deliver an NMDA receptor ant
121 BL/6 mice were implanted with a subcutaneous minipump that delivered a continuous infusion of secrete
122 s made hypertensive by implanting an osmotic minipump that delivered Ang II (0.7 mg/kg per day).
123 oventricular (i.c.v.) cannula and an osmotic minipump that delivered vehicle or 1.56 ng/h recombinant
124 f rats was implanted with Alzet((R)) osmotic minipumps that continuously released NTX into the latera
125 ion of arginine vasopressin (AVP) by osmotic minipump, the 117-kD band was markedly diminished, where
126 nfusion catheter connected to a subcutaneous minipump, the release of amino acids before and during a
127         Three weeks after the removal of the minipumps, the hearts of mice previously exposed to Ang-
128 ionitrile (BAPN) was administered by osmotic minipump to 38-week-old C57BL/6J male mice for 2 weeks.
129  and insulin was administered via an osmotic minipump to achieve moderate hyperglycemia.
130                       Inosine applied with a minipump to the rat sensorimotor cortex stimulated intac
131 am control solution was delivered by osmotic minipump to the retrolaminar region of one optic nerve o
132                                      Osmotic minipumps to infuse dDAVP, the V2-selective vasopressin
133     Subcutaneous injections of ibuprofen via minipumps to rats with a thoracic spinal cord transectio
134 nduction of disease or crucially via osmotic minipump two weeks after disease induction.
135 a continuous infusion with implanted osmotic minipumps, using a dose rate (3-6 mg kg-1 day-1) set to
136 bate, delivered at 37 degrees C from osmotic minipumps, was stable for 8 days as determined by its re
137                    Finally, using an osmotic minipump, we infused AS-PKCalpha into mice in which myoc
138                                      Osmotic minipumps were implanted in pregnant Sprague-Dawley rats
139         Three weeks after lesioning, osmotic minipumps were implanted that released recombinant human
140 yuridine (EdU)-a thymidine analog-containing minipumps were inserted at the time of MI induction.
141                                      Osmotic minipumps were used to infuse intracerebrally a specific
142             Subcutaneously implanted osmotic minipumps were used to infuse sustained low rates (0.15
143                                      Osmotic minipumps were used to treat normal rats with ET-1 for 5
144                                      Osmotic minipumps with a continuous infusion of Ang II (angioten
145 purpose, female mice were infused by osmotic minipumps with a single class II MHC-presented HY peptid
146          Rats were infused intravenously via minipumps with either saline, rat oxyntomodulin (0.47 nm

 
Page Top